AbbVie Inc. (NYSE: ABBV) will not pursue accelerated approval for Rova-T to treat small cell lung cancer. The stock price crashed $14.35 to close at $98.10.
No accelerated approval for AbbVie's Rova-T
March 22, 2018 at 17:39 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.